Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chikungunya virus infection disrupts lymph node lymphatic endothelial cell composition and function via MARCO
Cormac J. Lucas, … , Beth A.J. Tamburini, Thomas E. Morrison
Cormac J. Lucas, … , Beth A.J. Tamburini, Thomas E. Morrison
Published January 9, 2024
Citation Information: JCI Insight. 2024;9(4):e176537. https://doi.org/10.1172/jci.insight.176537.
View: Text | PDF
Research Article Immunology Virology

Chikungunya virus infection disrupts lymph node lymphatic endothelial cell composition and function via MARCO

  • Text
  • PDF
Abstract

Infection with chikungunya virus (CHIKV) causes disruption of draining lymph node (dLN) organization, including paracortical relocalization of B cells, loss of the B cell–T cell border, and lymphocyte depletion that is associated with infiltration of the LN with inflammatory myeloid cells. Here, we found that, during the first 24 hours of infection, CHIKV RNA accumulated in MARCO-expressing lymphatic endothelial cells (LECs) in both the floor and medullary LN sinuses. The accumulation of viral RNA in the LN was associated with a switch to an antiviral and inflammatory gene expression program across LN stromal cells, and this inflammatory response — including recruitment of myeloid cells to the LN — was accelerated by CHIKV-MARCO interactions. As CHIKV infection progressed, both floor and medullary LECs diminished in number, suggesting further functional impairment of the LN by infection. Consistent with this idea, antigen acquisition by LECs, a key function of LN LECs during infection and immunization, was reduced during pathogenic CHIKV infection.

Authors

Cormac J. Lucas, Ryan M. Sheridan, Glennys V. Reynoso, Bennett J. Davenport, Mary K. McCarthy, Aspen Martin, Jay R. Hesselberth, Heather D. Hickman, Beth A.J. Tamburini, Thomas E. Morrison

×

Figure 7

WT CHIKV infection impairs antigen acquisition by LECs in a MARCO-dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
WT CHIKV infection impairs antigen acquisition by LECs in a MARCO-depend...
(A) WT and MARCO–/– mice were mock inoculated (n = 5) or inoculated in the footpad with 1 × 103 PFU CHIKV 181/25 (n = 8) or WT CHIKV (n = 8) (2 independent experiments). At 72 hours after infection, mice were inoculated with 10 μg ova-488 in both calf muscles (20 μg total). As controls, naive WT and MARCO–/– mice were injected with 10 μg ova-488 and 5 μg polyI:C. Ova+ LECs in the popliteal LN were enumerated by flow cytometry at the indicated time points. (B) LNSC numbers in the popliteal LN following ova immunization. (C) Representative flow cytometry plots showing ova+ LECs. (D) The percentage and total number of ova+ LECs. (E) Representative flow cytometry plots showing ova+ LECs. (F) Percentage and number of ova+ LECs. (G) Representative flow cytometry plots showing ova+ LECs in mock-infected WT and MARCO–/– mice inoculated with polyI:C/ova-488. (H) Percentage and number of ova+ LECs. *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, by 1-way ANOVA with Tukey’s multiple-comparison test (B, D, and F) or Student’s t test (H).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts